Disciplina de Urologia, Faculdade de Medicina do ABC, Santo André, SP, Brasil.
Departamento de Insuficiência Cardíaca, Instituto do Coração (InCor) - Hospital das Clinicas, Universidade de São Paulo - USP, São Paulo, SP, Brasil.
Int Braz J Urol. 2024 Mar-Apr;50(2):119-135. doi: 10.1590/S1677-5538.IBJU.2023.0578.
Statins are one of the most prescribed classes of drugs worldwide to treat hypercholesterolemia and dyslipidemia. By lowering the level of cholesterol, the use of statin could cause a reduction in testosterone levels. The objective was to evaluate whether the continued use of statins in patients with hypercholesterolemia causes a deficiency in testosterone and other sex hormones.
Systematic Review with Meta-analysis, performed in Embase, Medline and Cochrane databases, until May 2023; PROSPERO CRD42021270424protocol. Selection performed by two independent authors with subsequent conference in stages. Methodology based on PRISMA statement. There were selected comparative studies, prospective cohorts (CP), randomized clinical trials (RCT) and cross-sectional studies (CSS) with comparison of testosterone levels before and after statin administration and between groups. Bias analysis were evaluated with Cochrane Tool, The Newcastle-Ottawa Scale (NOS), and using the Assess the Quality of Cross-sectional studies (AXIS) tool.
There were found on MedLine, Embase and Cochrane, after selected comparative studies, 10CP and 6RCT and 6CSS for the meta-analysis. In the Forrest plot with 6CSS, a correlation between patients with continuous use of statins and a reduction in total testosterone was evidenced with a statistically significant reduction of 55.02ng/dL (95%CI=[39.40,70.64],I²=91%,p<0.00001).In the analysis with 5RCT, a reduction in the mean total testosterone in patients who started continuous statin use was evidenced, with a statistical significance of 13.12ng/dL (95%CI=[1.16,25.08],I²=0%,p=0.03). Furthermore, the analysis of all prospective studies with 15 articles showed a statistically significant reduction in the mean total testosterone of 9.11 ng/dL (95%CI=[0.16,18.06],I²=37%,p=0.04). A reduction in total testosterone has been shown in most studies and in its accumulated analysis after statin use. However, this decrease was not enough to reach levels below normal.
Statins use causes a decrease in total testosterone, not enough to cause a drop below the normal range and also determines increase in FSH levels. No differences were found in LH, Estradiol, SHBG and Free Testosterone analysis.
他汀类药物是全球最常开的降胆固醇和血脂药物之一。通过降低胆固醇水平,他汀类药物的使用可能导致睾酮水平降低。本研究旨在评估高胆固醇血症患者持续使用他汀类药物是否会导致睾酮和其他性激素缺乏。
系统评价和荟萃分析,在 Embase、Medline 和 Cochrane 数据库中进行,截至 2023 年 5 月;PROSPERO CRD42021270424 方案。由两名独立作者进行选择,随后分阶段进行会议。方法基于 PRISMA 声明。选择了比较研究、前瞻性队列研究(CP)、随机临床试验(RCT)和横断面研究(CSS),比较了他汀类药物治疗前后和组间的睾酮水平。使用 Cochrane 工具、纽卡斯尔-渥太华量表(NOS)和评估横断面研究质量(AXIS)工具评估偏倚分析。
在 MedLine、Embase 和 Cochrane 上进行选择后,发现了 10 项 CP、6 项 RCT 和 6 项 CSS 进行荟萃分析。在 6 项 CSS 的 Forrest 图中,证据表明,连续使用他汀类药物的患者与总睾酮降低之间存在相关性,总睾酮降低具有统计学意义,为 55.02ng/dL(95%CI=[39.40,70.64],I²=91%,p<0.00001)。在分析 5 项 RCT 时,证据表明,开始连续使用他汀类药物的患者总睾酮平均水平降低,具有统计学意义,为 13.12ng/dL(95%CI=[1.16,25.08],I²=0%,p=0.03)。此外,对 15 篇文章的所有前瞻性研究进行分析,显示总睾酮平均水平降低 9.11ng/dL(95%CI=[0.16,18.06],I²=37%,p=0.04),具有统计学意义。大多数研究和他汀类药物使用后的累积分析均显示总睾酮降低。然而,这种下降还不足以导致低于正常水平。
他汀类药物的使用会导致总睾酮降低,不足以导致低于正常范围,也会导致 FSH 水平升高。在 LH、雌二醇、SHBG 和游离睾酮分析中未发现差异。